Relationship of plasma bone cytokines with hypercalcemia in cancer patients

Motellón, J.L; Jiménez, F. Javier; Miguel, F.; Jaras, M.J.; Díaz, Ana García; Hurtado, Jesús; Esbrit, Pedro

doi:10.1016/s0009-8981(00)00352-1

Cited by 13 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…34,35 It is not clear whether this cytokine causes hypercalcemia either directly or indirectly by increasing the effect of PTHrP on bone resorption. [36][37][38] At this time, IL-6-mediated hypercalcemia appears to be multifactorial.…”

Section: Discussionmentioning

confidence: 99%

Renal Cell Carcinoma Presenting with Paraneoplastic Hypercalcemic Coma: A Case Report and Review of the Literature

et al. 2007

View full text Add to dashboard Cite

We report a case of a 62-year-old woman with renal cell carcinoma (RCC) presenting with a hypercalcemiainduced coma. A laboratory evaluation indicated nonparathyroid-mediated hypercalcemia with an initial serum calcium level of 18.6 mg/dL. Our patient's parathyroid hormone (PTH)-related peptide level was undetectable. Initial imaging was negative, but PET scan identified a mass in the upper pole of the left kidney. Our patient underwent partial nephrectomy, and the mass was identified as RCC on final pathology. After surgery, her hypercalcemia resolved and PTH returned to normal limits. This case report describes a patient with RCC with the unusual presentation of hypercalcemic coma. We review the differential diagnosis of malignant hypercalcemia and the evaluation of hypercalcemia occurring with RCC. This case illustrates the need to carefully review and interpret all available data, especially when conventional testing in the work-up of hypercalcemia is unrevealing.

show abstract

Section: Discussionmentioning

confidence: 99%

Renal Cell Carcinoma Presenting with Paraneoplastic Hypercalcemic Coma: A Case Report and Review of the Literature

et al. 2007

View full text Add to dashboard Cite

show abstract

“…This observation may be attributable to the presence of undiagnosed bone metastases in the ‘negative’ control group, and may point to an inherent problem in study design (discussed earlier). However, these observations may alternatively reflect systemic, cytokine‐mediated acceleration of bone turnover 29 …”

Section: Diagnostic Usementioning

confidence: 99%

“…However, these observations may alternatively reflect systemic, cytokine-mediated acceleration of bone turnover. 29 Pecherstorfer et al . 30 reported significantly higher levels of urinary DPD in patients with MM as compared to healthy adults, patients with monoclonal gammopathy of undetermined significance (MGUS) or patients with postmenopausal osteoporosis.…”

Section: Diagnostic Usementioning

confidence: 99%

The use of molecular markers of bone turnover in the management of patients with metastatic bone disease

Seibel

2007

Clinical Endocrinology

View full text Add to dashboard Cite

SummaryBiochemical markers of bone turnover are widely used in clinical practice. These indices have been shown to be associated with the occurrence, prognosis and therapeutic response of malignant bone lesions. For example, markers of bone resorption are often elevated in patients with established bone metastases and while this may point to a role of these markers in the diagnostic workup of cancer patients, the available evidence does not permit any final conclusions as to the accuracy and validity of the presently used markers in the early diagnosis of bone metastases. Many bone turnover markers appear to respond to antiresorptive and antineoplastic therapies, and recent evidence from prospective trials suggests that the aim of bisphosphonate therapy should be to normalize rates of bone remodelling to optimize therapeutic and prognostic outcomes. However, it remains unknown whether the use of bone markers in the routine clinical setting has any defined beneficial effects on overall outcome in cancer patients. Clearly, bone turnover markers have insufficient diagnostic or prognostic value to be used in isolation; however, the combination of these markers with other diagnostic techniques may improve clinical assessment of patients with bone-seeking cancers. This article reviews the available evidence (as of August 2007) on the clinical use of bone turnover markers in the management of patients with metastatic bone disease.

show abstract

“…Conflicting evidence has been found for other cytokines. In a recent publication, interleukin‐lβ and TGF‐α were found to circulate at lower levels in hypercalcaemic compared to normocalcaemic individuals, with a wide variety of cancerous conditions 8 . Can we assume that the circulating levels of cytokines reflect activity at the bone remodelling surfaces?…”

mentioning

confidence: 99%

Bone markers in patients with multiple myeloma and monoclonal gammopathy of undetermined significance

Glendenning

Vasikaran

2002

Internal Medicine Journal

View full text Add to dashboard Cite

Relationship of plasma bone cytokines with hypercalcemia in cancer patients

Cited by 13 publications

References 29 publications

Renal Cell Carcinoma Presenting with Paraneoplastic Hypercalcemic Coma: A Case Report and Review of the Literature

Renal Cell Carcinoma Presenting with Paraneoplastic Hypercalcemic Coma: A Case Report and Review of the Literature

The use of molecular markers of bone turnover in the management of patients with metastatic bone disease

Bone markers in patients with multiple myeloma and monoclonal gammopathy of undetermined significance

Contact Info

Product

Resources

About